Renal cell carcinoma (RCC) is a complex disease, known as the most common form of kidney cancer. Various histological subtypes of RCC have been identified including clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophore RCC (chRCC). In 2020, there were approximately 74,000 new cases and 15,000 deaths in the United States. One-third of RCC patients commonly develop local recurrence or metastases which are difficult to treat and therefore RCC remains a leading cause of mortality. Despite advances in treatment, the 5-year survival rate of metastatic RCC remains to be less than 15%.
There has been significant progress towards the treatment of RCC with early surgical resection in addition to novel tyrosine kinase inhibitors immunotherapy using antibodies to checkpoint block inhibitors alone and in combination (anti-PD1 or anti-CTLA4). However, many RCC patients continue to suffer from tumor recurrence and distant metastasis. Due to poor prognosis of RCC, this has led to studies to understand the molecular mechanisms underlying RCC and investigate the factors which influence the progression of the disease and how to help improve survival outcome for RCC patients. This includes the identification of novel biomarkers, tumor suppressors, the role of cancer associated fibroblasts and many other factors.
This Research Topic aims to provide insight into factors which influence the progression of RCC. Topics of interest include:
-How tumor suppressors influence the progression of RCC
-The role and influence of biomarkers in RCC
-How cancer associated fibroblasts influence RCC progression
-Factors which influence the progression of RCC
Renal cell carcinoma (RCC) is a complex disease, known as the most common form of kidney cancer. Various histological subtypes of RCC have been identified including clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophore RCC (chRCC). In 2020, there were approximately 74,000 new cases and 15,000 deaths in the United States. One-third of RCC patients commonly develop local recurrence or metastases which are difficult to treat and therefore RCC remains a leading cause of mortality. Despite advances in treatment, the 5-year survival rate of metastatic RCC remains to be less than 15%.
There has been significant progress towards the treatment of RCC with early surgical resection in addition to novel tyrosine kinase inhibitors immunotherapy using antibodies to checkpoint block inhibitors alone and in combination (anti-PD1 or anti-CTLA4). However, many RCC patients continue to suffer from tumor recurrence and distant metastasis. Due to poor prognosis of RCC, this has led to studies to understand the molecular mechanisms underlying RCC and investigate the factors which influence the progression of the disease and how to help improve survival outcome for RCC patients. This includes the identification of novel biomarkers, tumor suppressors, the role of cancer associated fibroblasts and many other factors.
This Research Topic aims to provide insight into factors which influence the progression of RCC. Topics of interest include:
-How tumor suppressors influence the progression of RCC
-The role and influence of biomarkers in RCC
-How cancer associated fibroblasts influence RCC progression
-Factors which influence the progression of RCC
